Current and future medical treatment for endometriosis

Fuminori Taniguchi
In: Proceedings for Annual Meeting of The Japanese Pharmacological Society · 2023 · vol. 97(0) , pp. 1–B · doi:10.1254/jpssuppl.97.0_1-b-s17-1 · W4390654017
OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Researchers investigated potential novel endometriosis treatments, finding that parthenolide and selective estrogen receptor modulators suppressed inflammation and proliferation, while Kampo medicine raised pain thresholds and inhibited IL-33.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-05 · read from full text ⓘ

This presentation reviews the rising incidence of endometriosis, attributing it to demographic shifts such as delayed childbearing and increased menstrual frequency. It highlights potential novel therapeutic agents, including IAP inhibitors, parthenolide, and selective estrogen receptor modulators, which suppress inflammation and proliferation via NF-kB inhibition in human cells and mouse models. The authors also report that Kampo medicine can raise pain thresholds and inhibit IL-33 expression in endometriotic lesions, while noting the use of bioluminescence technology for non-invasive observation of early disease stages. This paper is centrally about endometriosis — specifically exploring current pharmacological treatments and future drug development strategies for the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Although it is difficult to determine the actual incidence of endometriosis, an increase in the frequency of menstrual periods due to women's entry into the workforce and the trend toward late childbearing and low fertility are thought to be the reasons for the rising incidence. The characteristics of endometriosis include the need to preserve fertility in the majority of cases, and the association of dysmenorrhea in young patients with future development of endometriosis. We presented that IAP (Inhibitor of apoptotic protein) inhibitors have the potential to be novel agents for the treatment of endometriosis. A medicinal herb parthenolide and selective estrogen receptor modulator, which are found in a number of plants, suppressed inflammation and proliferation in human endometriosis cells and shrink mouse foci through NF-kB inhibition. We found that Kampo medicine raised the pain threshold in mice and inhibited IL-33 expression in endometriotic lesions. Recently, we have applied bioluminescence technology and knockout mouse models to non-invasively observe early lesions. I will explain the possibility of new therapeutic agents for endometriosis.
Full text 1,329 characters · extracted from oa-doi-fallback · click to expand
第97回日本薬理学会年会 セッションID: 97_1-B-S17-1 会議情報 主催: 公益社団法人日本薬理学会 会議名: 第97回日本薬理学会年会 回次: 97 開催地: 神戸 開催日: 2023/12/14 - 2023/12/16 シンポジウム 子宮内膜症に対する薬物治療の現状と未来 詳細 抄録 Although it is difficult to determine the actual incidence of endometriosis, an increase in the frequency of menstrual periods due to women's entry into the workforce and the trend toward late childbearing and low fertility are thought to be the reasons for the rising incidence. The characteristics of endometriosis include the need to preserve fertility in the majority of cases, and the association of dysmenorrhea in young patients with future development of endometriosis. We presented that IAP (Inhibitor of apoptotic protein) inhibitors have the potential to be novel agents for the treatment of endometriosis. A medicinal herb parthenolide and selective estrogen receptor modulator, which are found in a number of plants, suppressed inflammation and proliferation in human endometriosis cells and shrink mouse foci through NF-kB inhibition. We found that Kampo medicine raised the pain threshold in mice and inhibited IL-33 expression in endometriotic lesions. Recently, we have applied bioluminescence technology and knockout mouse models to non-invasively observe early lesions. I will explain the possibility of new therapeutic agents for endometriosis. © 2023 本論文著者

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisdysmenorrhea

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK